We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Generation Bio Co (GBIO) USD0.0001

Sell:$8.03 Buy:$8.05 Change: $0.03 (0.37%)
Market closed |  Prices as at close on 5 August 2022 | Switch to live prices |
Change: $0.03 (0.37%)
Market closed |  Prices as at close on 5 August 2022 | Switch to live prices |
Change: $0.03 (0.37%)
Market closed |  Prices as at close on 5 August 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Generation Bio Co. is genetic medicines to provide treatments of rare and prevalent diseases. The Company through its non-viral genetic medicine platform, is engaged in developing genetic medicines to provide genetic payloads, which include large and multiple genes to a range of cell types across a range of diseases. It is comprised of three component technologies: ceDNA, ctLNP and ceDNA manufacturing process. ceDNA is an engineered, double-stranded, linear, covalently closed-ended deoxyribonucleic acid (DNA) construct, which includes the gene of interest and associated regulatory sequences. It has produced ceDNA constructs of approximately eight kilobases. Its ctLNP delivery system builds upon clinically validated lipid nanoparticles and is designed to allow for repeat dosing of a genetic payload without stimulating an immune response, such as antibody production. Its ceDNA manufacturing process uses its own cell-free rapid enzymatic synthesis (RES) to produce ceDNA.

Contact details

United States
+1 (857) 5295908

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$428.16 million
Shares in issue:
57.09 million
United States
US dollar

Key personnel

  • Cameron Mcdonough
    President, Chief Executive Officer, Director
  • Matthew Norkunas
    Chief Financial Officer
  • Antoinette Paone
    Chief Operating Officer
  • Matthew Stanton
    Chief Scientific Officer
  • Douglas Kerr
    Chief Medical Officer
  • Tracy Zimmermann
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.